MorphoSys AG Enters Antibody Pact With U.S. Merck & Co., Inc.
MARTINSRIED, GERMANY -- (MARKET WIRE) -- 12/14/2005 -- MorphoSys AG (Frankfurt: MOR; Prime Standard Segment, TecDAX) announced today that it has signed a five-year license agreement with U.S. pharmaceutical company Merck & Co., Inc. for the use of MorphoSys's HuCAL GOLD® and AutoCAL™ technologies in research and development of human therapeutic antibodies.